1. The document discusses using a PK/PD approach to predict the efficacy of repurposed antiviral drugs for COVID-19. It analyzes drugs like lopinavir/ritonavir, remdesivir, favipiravir, and hydroxychloroquine. 2. For lopinavir/ritonavir, the high protein binding restricts achievement of therapeutic drug levels in the lungs. Clinical trials showed a lack of efficacy. 3. For remdesivir, the prodrug is converted to a nucleoside metabolite with low levels in the lungs. While initial trials showed clinical improvement, more data is still needed.